Navigation Links
Spherics, Inc. Offers Extended Release Formulation for Sustained and Stable Levodopa Levels
Date:8/25/2008

WELLESLEY HILLS, Mass., Aug. 25 /PRNewswire/ -- Joseph F. Finn, Jr., C.P.A. ("Finn"), Assignee of the assets of Spherics, Inc. ("Spherics") for the benefit of creditors, announced today that all pharmaceutical intellectual property will be sold at a sealed bid auction on October 10, 2008.

SRx-501 is an extended release formulation of Levodopa-Carbidopa that is the current gold standard treatment for Parkinson's disease, with global sales estimated at approximately $250 million. Significant PK issues with the currently available product include erratic absorption, high inter-subject variability and a steep wearing-off rate under its three+ times daily dosing regimen.

Spherics has developed a multi-layer tablet allowing

(i) faster on-set than Sinement CR,

(ii) improved sustained plasma levels above minimum effective concentration enabling a 1x or 2x-day dosing,

(iii) reduced inter- and intra-subject variability that will reduce dyskinesia and improve tolerability.

SRx-501 will also be developed under 505(b)(2) guidelines for the FDA. The Company estimates that the remaining trials will lead to an NDA submission in 2011. There is human 'proof of concept' clinical data available. A supply of clinical drug product is available for an approved Phase II clinical study in Parkinson patients.

Persons interested in bidding must sign a Confidentiality Agreement ("CA") obtained from Finn's office - jffinnjr@earthlink.net or 781-237-8840. They will then receive a bid package and access to the Spherics electronic data room.

About Spherics

Spherics has built a strong intellectual property position around its drug delivery technologies and products. The Company has a broad range of issued US and international patents that they have applied to their four central nervous system products. These patents cover polyanhydride-based bioadhesive polymers and nanotechnology (PIN)
'/>"/>

SOURCE Spherics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. RediClinic Offers Affordable New Plan Clinically Shown to Double a Persons Chance to Stop Smoking
2. Spine Institute of Louisiana Offers Cervical Spine Motion Preservation as an Alternative to Fusion Surgery
3. CVS/pharmacy Offers Flu Vaccinations in Over 4,000 Stores
4. Spit for the Cure Offers Unique Opportunity for Women to Participate in Breast Cancer Research
5. Concentra Offers Flu Vaccines to Keep America Working
6. New Report by Pediatricians Finds Gaps in Preparing to Protect Kids From Pandemic Flu, Offers Recommendations
7. UPDATE: New Report by Pediatricians Finds Gaps in Preparing to Protect Kids From Pandemic Flu, Offers Recommendations
8. New UNAIDS Report Offers Encouraging News, But Most HIV-Positive Mothers Still Not Getting the Care & Treatment They Need
9. New Data Published in The Lancet Show GSKs ROTARIX(R) Offers Protection Against the Most Common Circulating Rotavirus Types
10. Researcher Investigates Disparities in Doctor-Patient Information Exchange During Clinical Trial Offers
11. New Report Offers Hope for Closing Health Gap for African Americans, With Nearly 700 Medicines in Pipeline
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)TARRYTOWN, N.Y., Dec. 4 Bayer Diabetes Care today announced the three grand prize winners of Bayer,s "Express Your Simple Win Creativity Contest." Nick Jonas, of the Jonas Brothers, selected the winn
(Date:12/4/2009)RARITAN, N.J., Dec. 4 Depression, anxiety disorder, bipolar disorder, Attention Deficit Hyperactivity Disorder (ADHD), sleep disorder and migraine: These are among the comorbidities reported to occur
(Date:12/3/2009)MADISON, N.J., Dec. 3 A genetic variation that may indicate a patient,s risk of developing a potentially life-threatening blood disorder if exposed to certain pharmaceutical therapies or chemicals is
Breaking Medicine Technology:Bayer 'Express Your Simple Win Creativity Contest' Grand Prize Winners Announced 2Bayer 'Express Your Simple Win Creativity Contest' Grand Prize Winners Announced 3Looking Ahead to AES 2009: New Insights on Comorbidities and Other Considerations for Epilepsy Treatment 2Looking Ahead to AES 2009: New Insights on Comorbidities and Other Considerations for Epilepsy Treatment 3Quest Diagnostics Reveals New Genetic Discoveries for Testing for Leukemia, Lymphoma and Blood Clotting at 51st ASH Meeting and Exposition 2Quest Diagnostics Reveals New Genetic Discoveries for Testing for Leukemia, Lymphoma and Blood Clotting at 51st ASH Meeting and Exposition 3Medigap Plans in Illinois to Benefit From Medicare Advantage Reimbursement Cuts 52935 1Medigap Plans in Illinois to Benefit From Medicare Advantage Reimbursement Cuts 52935 2Sunshine Heart Provides C Pulse U S Clinical Update 52931 1Sunshine Heart Provides C Pulse U S Clinical Update 52931 2Sunshine Heart Provides C Pulse U S Clinical Update 52931 3Sunshine Heart Provides C Pulse U S Clinical Update 52931 4Diabetes Screening Comes Home with A1c Testing 52927 1Diabetes Screening Comes Home with A1c Testing 52927 2
...N, Pa., March 14 Isolagen(TM), Inc.,(Amex: ILE )...pproximately,120 patients in its Phase II/III Stud...for the treatment of moderate to severe acne scars...linical sites across the U.S., have,now commenced....at promise for the,treatment of acne scars and are...
... Suggest Majority of Pompe Patients May Be Amenabl...apy, CRANBURY, N.J., March 13 Amicus Therapeutic...lecule, orally administered,pharmacological chaper...nnounced today that the Company will present posit...ee Phase 1 studies of AT2220 (1-deoxynojirimycin,H...
Other Medicine Technology:Isolagen, Inc. Completes Enrollment in Isolagen Therapy(TM) Phase II/III Acne Scar Study 2Isolagen, Inc. Completes Enrollment in Isolagen Therapy(TM) Phase II/III Acne Scar Study 3Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220 2Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220 3Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220 4
(Date:12/5/2009)--In Youngest Babies, This Type of Blood Cancer Is Most Challenging-- ,, PHILADELPHIA and NEW ORLEANS, Dec. 5 Pediatric oncologists have identified specific genes, dubbed partner genes, that fuse w
(Date:12/5/2009)AVIVA today announced the launch of International Solutions, an innovative new international private medical insurance plan which follows the acclaimed modular design of its UK equivalent. In addition
(Date:12/4/2009)NEW YORK, Dec. 4 Thousands of KPMG LLP employees came together in more than 90 offices nationwide today, to participate in a community service event which combines the audit, tax and advisory firm,s
(Date:12/4/2009)KANSAS CITY, Mo., Dec. 4 The large, two-day free health clinic sponsored by the National Association of Free Clinics (NAFC) in Kansas City on Wednesday and Thursday is not just for the sick but also
(Date:12/4/2009)Late recurrence is a risk for some pediatric cancers, particularly Ewing sarcomas and tumors of the central nervous system, according to a new study published online December 4 in the Journal of the
Breaking Medicine News(10 mins):Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 2Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 3Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 4Health News:AVIVA's Private Health Insurance Products Solutions Go International 2Health News:KPMG Employees Provide 'Holiday Bear Hugs' and Books in Firmwide Service Day for Children 2Health News:Free Health Clinic Event Is Not Just for the Sick 2
...State University researchers have now developed a ...marrow derived stem cells to be grown in sufficien... faster growth of// tissues. This overcomes the cu...ic conditions encountered by adult stem cells with...
...akthrough, scientists present the first proof that...use of the common cold.// So, if your mother ...g a cold, it seems she may have had a point. ... this week’s The Oxford Journal of Family Practice...
...rnment in its determination to gear up to meet the... committee to keep a close watch on bird flu cases...imal Husbandry Secretary P M A Hakeem said "Though...poultry industry". The Secretary said the Central ...
...sults showed that people who lived longer had a hi...position. The research study was carried out by Dr...ol of Public Health who reported their finding in ... with a score more than 130 are considered gifted ...
...cer and other cancers are mainly caused by cigaret...eases the risk of cancer occurrence. In order to r...merican Tobacco company is in the process of testi...ttes to find its efficacy and carcinogen content e...
...akthrough, which could eventually lead to a practi...irus, scientists from the US National Cancer Insti...the human body to produce chemicals that block HIV...a. The researchers have successfully modifie...
Other Medicine News:Health News:Perfusion bioreactor could enhance stem cell research and application in the future 2Health News:Scientist affirm mother’s advice 2Health News:Avian Influenza: Government to set up expert committee 2Health News:Genetically modified bacteria to combat HIV 2
AHFS Patient Drug Information
The 5 Minute Herb & Dietary Supplement Consult
Quality Module QS I
...mbination of the Aliquoting System RSD 800A with a... turns out in an efficient System and a complete s...all important front-end and back-end features: cen...ation, sample quality control, decapping, barcode ...
Medicine Products: